The MMP-9 plasma levels decreased from 125.6 ng/mL in the tumor control group to 43.1 ng/mL and 32.8 ng/mL in the CAPE and CAPPE–fed groups, respectively (Figure 8F). The gene discussed is MMP9; the disease is neoplasm.